Dr Reddy's launches halometasone cream in India

Dr Reddy's Laboratories Ltd has launched Execare (halometasone cream 0.05 per cent) in India for the treatment of acute/chronic steroid responsive dermatoses and vitiligo. 

Execare is a potent steroid and is recommended as an alternative to betamethasone dipropionate and mometasone furoate. 

The halometasone monohydrate is known to have very good anti-inflammatory action with significant safety and tolerability profile. Halometasone acts by blocking their production, thus acting as an anti-inflammatory agent.

With this launch, Dr Reddy's becomes the first company to introduce this molecule in India, a press release said. 

The topical steroid market size is about Rs 120 crore and growing at 14 per cent according to ORG figures of May 2009.


Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Trump wants more mental health care; Alabama says it's trying